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Abstract Human hepatocytes are particularly exposed to
genotoxins, and nucleotide excision repair (NER) in these cells
is essential for the maintenance of genome integrity. To
characterize NER under conditions that closely resemble the
pathway in vivo, we report the preparation and use of primary
human fetal liver extracts to define the repair of a 1,3-intrastrand
d(GpTpG)-cisplatin DNA lesion. Endonucleolytic cleavage at
unique sites on either side of the adduct occurs at similar
positions to the dominant NER incisions that have been reported
for HeLa extracts. However, incisions effected by primary
hepatocyte extracts are more precise as no secondary cleavage
sites are detected 5P and 3P to the cisplatin lesion. ß 2002
Published by Elsevier Science B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
There are several DNA repair mechanisms that counteract
the potentially cytotoxic and carcinogenic e¡ects of mutagens.
These include base excision repair, transcription-coupled re-
pair and nucleotide excision repair (NER). NER is responsi-
ble for the removal of bulky helix-distorting lesions in an
intricate mechanism that involves several protein^DNA and
protein^protein interactions [1]. The pathway is initiated by
factors that recognize damaged DNA and recruit TFIIH, the
multi-unit transcription factor [2]. XPB and XPD, which are
helicase components of TFIIH, unwind DNA around the le-
sion. An open complex is formed to allow XPF-ERCC1 and
XPG endonucleases access to incise the damaged DNA strand
at sites 5P and 3P to the lesion [3]. A single-stranded oligomer
of 25^32 nucleotides, which includes the damaged site, is then
removed. Finally, using the undamaged strand as template,
NER is completed by the formation of a repair patch, which
is carried out by PCNA-dependent DNA polymerases and a
DNA ligase (reviewed in [4^7]). In humans, NER is required
to neutralize the potentially carcinogenic DNA lesions that
are caused by chemical mutagens and ultraviolet (UV) irradi-
ation. Mutagens that are absorbed from the entire gastroin-
testinal tract are conveyed to the liver via the portal circula-
tion. Hepatocytes are thus particularly exposed to ingested
mutagens [8]. An example is a£atoxin, which is also a power-
ful hepatocarcinogen. Another common cause of liver cancer,
persistent hepatitis B virus (HBV) infection, is thought to
inhibit NER by a mechanism that underlies hepatocarcino-
genesis [9^12]. Thus, de¢ning hepatic NER is central to under-
standing the maintenance of hepatocyte genome integrity and
the etiology of liver cancer. To analyze NER under conditions
that closely resemble hepatocyte DNA repair in situ, we used
primary extracts from human fetal liver to e¡ect repair of a
de¢ned 1,3-intrastrand d(GpTpG)-cisplatin DNA adduct. The
data indicate that incision steps of NER are more precisely
regulated in primary human liver extracts and the pathway in
vivo may involve an accessory function that is absent from
cells that are selected in culture.
2. Materials and methods
2.1. Generation and analysis of circular duplex DNA containing a
site-speci¢c intrastrand cisplatin crosslink
Preparation of duplex modi¢ed M13 DNA containing a unique 1,3-
intrastrand cisplatin adduct was according to the methods of Moggs
et al. with minor modi¢cations [13]. Brie£y, a synthetic 24-mer oligo-
nucleotide (5P-TCTTCTTCTGTGCACTCTTCTTCT-3P, Integrated
DNA Technologies Inc.) was platinated at the unique GTG sequence
by incubation for 16 h at 37‡C in a bu¡er containing 500 WM
Na2HPO4, 500 WM NaH2PO4, 3 mM NaCl with or without (control)
a two-fold molar excess of cis-platinum(II)-diamine dichloride (Sig-
ma). The platination was stopped by the addition of NaCl to a ¢nal
concentration of 500 mM. Products were puri¢ed by exclusion chro-
matography (Sephadex G-25) and the e⁄ciency of each reaction was
con¢rmed using denaturing polyacrylamide gel electrophoresis
(PAGE) with autoradiography. After 5P phosphorylation, control
and platinated oligonucleotides were puri¢ed using preparative
PAGE.
To synthesize covalently closed circular DNA (cccDNA) with the
site-speci¢c platinum adduct, a 5^10 times molar excess of control or
platinated oligonucleotide (70 ng) was annealed to complementary
sequences on 10 Wg of modi¢ed single-stranded M13 DNA
(M13mp18GTG). Hybridized oligonucleotides were then extended
by T4 DNA polymerase and formation of the covalently closed cir-
cular duplex DNA was completed by T4 DNA ligase. To remove
single-stranded, linear and nicked M13mp18GTG-derived DNAs,
each reaction mixture was treated with T5 exonuclease (0.5 Wg per
reaction) [14]. After heat inactivation of the T5 exonuclease, cccDNA
was puri¢ed by exclusion chromatography (Sephacryl S-400) and ef-
fective puri¢cation of cccDNA was con¢rmed using agarose gel elec-
trophoresis.
To con¢rm the 1,3-intrastrand d(GpTpG)-cisplatin crosslink, con-
trol (Con-GTG) and platinated (Pt-GTG) cccDNA samples were di-
gested with ApaLI and HindIII (Amersham Life Science), and prod-
ucts analyzed by agarose gel electrophoresis. The platination target
site is located at a unique ApaLI recognition sequence, and resistance
to digestion with this enzyme is diagnostic for correct platination. The
precise location of the cisplatin adduct was determined by primer
extension analysis. 20 pmol of a synthetic 17-mer oligonucleotide
(5P-CGCCCTCGAGCAGCAAA-3P, Pt-GTG(+38)), which is comple-
mentary to a sequence 38 nucleotides downstream of the GTG plati-
nation target, was used to prime 50 fmol of ApaLI-digested Con-GTG
or Pt-GTG. The oligonucleotide was extended by polymerization with
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thermal cycling (Sequitherm II cycle-sequencing kit, Epicentre Tech-
nologies Inc.).
2.2. Preparation of nuclear extracts from human fetal hepatic tissue
Ethical approval for acquiring fetal liver tissue was obtained from
the University of the Witwatersrand Committee for Research on Hu-
man Subjects (Protocol Number M990519). Prior to elective termina-
tion of pregnancy, voluntary informed consent was given by patients
to allow the use of fetal tissue. The procedure for the preparation of
nuclear protein extracts included several modi¢cations to the proce-
dure described by Gorski et al. [15]. Complete livers from fetuses of 14
weeks gestational age (approximately 10 g in each case) were removed
immediately post abortion. They were submerged in a solution con-
taining 0.9% NaCl and all subsequent procedures were carried out on
ice. The livers were minced, washed three times in 20 ml of 0.9%
NaCl, then resuspended in 25 ml of bu¡er H (25 mM KCl, 0.5 mM
spermidine, 0.15 mM spermine, 1 mM EDTA, 2 M sucrose, 10%
glycerol, 1.0 mM PMSF and 10 mM HEPES, pH 7.9) and homoge-
nized thoroughly with a blender. To isolate nuclei, the homogenate
was layered on a cushion of the sucrose-containing bu¡er H then
centrifuged for 30 min at 80 000Ug. Pelleted nuclei were removed
and incompletely homogenized tissue at the interface of the sucrose
cushion was subjected to re-isolation of the nuclei as described above.
Pooled nuclei were lysed by gentle suspension in 10 ml of bu¡er L
(100 mM KCl, 3 mM MgCl2, 0.1 mM EDTA, 10% glycerol, 1.0 mM
PMSF, and 10 mM HEPES, pH 7.9). 1 ml of a saturated solution of
ammonium sulfate (approximately 4 M) was added. Samples were
incubated on ice with gentle agitation for a further 30 min then cen-
trifuged at 90 000Ug to remove precipitated chromatin. Solid ammo-
nium sulfate (0.35 g per ml of recovered supernatant) was added
slowly over a period of 30 min, then incubated with shaking for a
further 2 h. Nuclear proteins were recovered by centrifugation
(95 000Ug for 30 min), pooled and then resuspended in 750 Wl of
dialysis bu¡er (40 mM KCl, 0.1 mM EDTA, 10% glycerol and 25
mM HEPES, pH 7.9). After extensive dialysis, the nuclear protein
preparation was aliquoted in 20 Wl volumes, snap-frozen in liquid
nitrogen and stored at 380‡C for no more than 6 months. Using
this procedure, the yield of nuclear protein was routinely 300^400
Wg per gram of liver tissue and at a concentration of approximately
6 Wg/Wl in the ¢nal extract.
2.3. DNA repair analysis
To measure DNA repair patch synthesis, mixtures (10 Wl) were set
up that contained 25 Wg of nuclear protein extract, 5 WCi of
[K-32P]dCTP, 20 WM of each dNTP, 70 mM KCl, 7.5 mM MgCl2,
0.9 mM dithiothreitol (DTT), 0.4 mM EDTA, 40 mM creatine phos-
phate, 0.5 Wg creatine phosphokinase, 4% glycerol, 0.35 mg/ml of
bovine serum albumin, 45 mM HEPES (pH 7.9) and 50 ng Con-
GTG or Pt-GTG DNA. Following incubation at 30‡C for 30 min,
puri¢ed DNA was digested with HindIII and EcoRI. The products
were resolved using denaturing PAGE, and labeled restriction frag-
ments were detected autoradiographically.
Detection of excised cisplatin-containing DNA fragments and map-
ping of 5P incision sites were based on the method described by Shivji
et al. [14]. A 10 Wl reaction, which contained 25 Wg of nuclear protein
extract, 70 mM KCl, 7.5 mM MgCl2, 0.9 mM DTT, 0.4 mM EDTA,
40 mM creatine phosphate, 0.5 Wg creatine phosphokinase, 4% glyc-
erol, 0.35 mg/ml of bovine serum albumin and 45 mM HEPES (pH
7.9), was preincubated at 30‡C for 5 min. The repair reaction was
initiated by adding Con-GTG or Pt-GTG and allowed to proceed for
a further 30 min. To map the position of 3P incisions, extension re-
actions using the Pt-GTG(+38) oligonucleotide as primer were per-
formed on puri¢ed incised DNA intermediates. To detect excised
platinated fragments and 5P incisions, 12 ng (2 Wl) of a synthetic 34-
mer oligonucleotide (anti-PtGTG, 5P-GGGGGAAGAGTGCACAG-
AAGAAGAGGCCTGGTCC-3P) was added to the repair reaction
and then heated to 95‡C for 5 min. After cooling to room temper-
ature, insoluble material was removed by centrifugation. A cocktail
containing 0.13 U modi¢ed T7 DNA polymerase (Sequenase, Amer-
sham Life Science) and 2.0 WCi [K-32P]dCTP, 5 mM DTT, 10 mM
Tris^HCl (pH 7.5) in 1 Wl was added to each sample and the tubes
were incubated at 37‡C for 5 min. The ¢nal dNTP concentration was
then adjusted to 1 WM for dATP, dGTP, dTTP and 0.5 WM for dCTP
by adding 1.5 Wl of an appropriate dNTP mix, and the reaction kept
at 37‡C for a further 10 min. The samples were resolved on a 14%
denaturing polyacrylamide gel alongside a sequencing ladder that
served as molecular weight marker. Radioactive DNA fragments
were detected using autoradiography.
3. Results
3.1. Analysis of cccDNA containing a single 1,3-intrastrand
d(GpTpG)-cisplatin crosslink
To prepare the Pt-GTG substrate, a 1,3-intrastrand cispla-
tin crosslink was generated in a 24-mer oligonucleotide at its
single d(GpTpG) triplet and formation of the desired 1,3-in-
trastrand d(GpTpG)-cisplatin adduct was veri¢ed using dena-
turing PAGE analysis. Compared to the mock-platinated oli-
gonucleotide, the 1,3-d(GpTpG) adduct retards electrophoretic
mobility of the oligonucleotide by the equivalent of approx-
imately one nucleotide (Fig. 1A). The increase is due to struc-
tural distortion of the DNA backbone, and addition of +227
Da by the cisplatin adduct [16]. Overplatination with forma-
tion of additional adducts is characterized by a larger molec-
ular weight smear on PAGE analysis ([14] and data not
shown). Incorporation of the platinated and mock-treated oli-
gonucleotides into Pt-GTG and Con-GTG cccDNA initially
involves their hybridization to a complementary sequence of a
single-stranded M13 derivative (M13mp18GTG). Thereafter,
DNA polymerase extends the oligonucleotides and the syn-
thetically circularized strand is ligated to complete formation
of the cccDNA. At completion of the reaction, nicked circular
and linear M13mp18GTG-derived DNA were present in ad-
dition to cccDNA. T5 exonuclease treatment with exclusion
Fig. 1. Analysis of control (Con-GTG) and platinated (Pt-GTG)
cccDNA substrates. A: Electrophoretic mobility of control (1) and
platinated (2) oligonucleotides. The platinated 24-mer has a mobility
of approximately +1 DNA nucleotide relative to the control. B: Pu-
ri¢cation of cccDNA. M13mp18GTG ssDNA prior to circulariza-
tion (lane 1), then after circularization with control (lane 2) and
platinated (lane 3) oligonucleotide primers are shown. Con-GTG
(lane 4) and Pt-GTG (lane 5) cccDNA are demonstrated following
treatment with T5 exonuclease. Mobilities of nicked circular (nc),
linear, covalently closed circular (ccc) and single-stranded (ss) DNA
are indicated. C: Restriction digestion analysis of puri¢ed cccDNA.
Undigested (lane 1), HindIII- (lane 2) and ApaLI- (lane 3) treated
Con-GTG are indicated, as well as undigested (lane 4), HindIII-
(lane 5) and ApaLI- (lane 6) treated Pt-GTG. D: Primer extension
analysis. Sequencing ladder of RF M13mp18GTG DNA and primer
extension of ApaLI-treated Con-GTG and untreated Pt-GTG are in-
dicated.
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chromatography removed all but the desired Pt-GTG and
Con-GTG cccDNA products (Fig. 1B).
ApaLI digestion and primer extension analysis con¢rmed
the presence of the 1,3-intrastrand d(GpTpG)-cisplatin cross-
link in puri¢ed Pt-GTG cccDNA. The platinated d(GpTpG)
sequence is located within a unique ApaLI recognition se-
quence of the cccDNA, and renders the site resistant to re-
striction by ApaLI (Fig. 1C). Also, the cisplatin crosslink ar-
rests primer extension at the targeted d(GpTpG) triplet on Pt-
GTG and this corresponds to the site of termination when
using the ApaLI-digested Con-GTG DNA as template (Fig.
1D). Taken together, these data con¢rm that site-speci¢c
platination has been achieved at the intended d(GpTpG) trip-
let of the puri¢ed covalently closed circular Pt-GTG NER
substrate. Pt-GTG DNA with a unique 1,3-intrastrand
d(GpTpG)-cisplatin crosslink has been shown to be a good
substrate for vertebrate NER [13]. The single adduct allows
detailed analysis of NER, and is thus ideally suited to de¢ning
steps of this pathway in previously uncharacterized cell ex-
tracts.
3.2. DNA repair patch synthesis by fetal liver extracts
The cisplatin lesion is located between HindIII and EcoRI
restriction sites of Pt-GTG (Fig. 2A). These restriction diges-
tion sites £ank the previously reported 5P and 3P NER inci-
sions of HeLa extracts [13] and are thus ideally suited to
locating repair patch synthesis. To demonstrate repair synthe-
sis in the area of the cisplatin adduct, Pt-GTG and Con-GTG
DNA were initially incubated with the fetal liver extract in the
presence of [K-32P]dCTP. Thereafter, digestion of the puri¢ed
cccDNA with HindIII and EcoRI revealed that most of the
repair synthesis occurred in a fragment of 57 nucleotides in
length (Fig. 2B). This size corresponds to that of the HindIII/
EcoRI restriction fragment that encompasses the repair patch.
The labeled fragment of 65 nucleotides was only observed
with the damaged substrate and may result from restriction
star activity by the combination of EcoRI and HindIII. No
labeling of the 57 nucleotide fragment from Con-GTG was
detectable (Fig. 2B) and veri¢es that speci¢c repair synthesis
occurs in the platinated cccDNA substrate.
3.3. Mapping of NER 3P and 5P incisions by fetal liver extracts
To map 3P NER incision sites generated by the fetal liver
extract, a primer extension assay using the Pt-GTG(+38) oli-
gonucleotide was performed. This oligonucleotide is comple-
mentary to a sequence 38 nucleotides downstream of the
unique platinated site of Pt-GTG. Together with sequencing
of the M13mp18GTG RF DNA, primer extension reveals that
a single 3P incision is located nine phosphodiester bonds from
the site of platination (Fig. 3A). This is similar to the main 3P
incision that has been documented when using HeLa extracts
[13]. Primer extension took place e⁄ciently when using Con-
GTG DNA as the template. Intensively labeled high molec-
ular weight DNA fragments were generated, but only the area
of interest for detection of incision sites is shown in Fig. 3A.
The secondary 3P incision e¡ected by HeLa extracts, which is
eight nucleotides from the cisplatin adduct, was undetectable.
The proportion of substrate with the 3P incision represented
approximately 20% of the total Pt-GTG that was included in
the reaction mixture. In the remaining 80% of substrate DNA,
primer extension was terminated at the platination site (Fig.
3A). The e⁄ciency of 3P incision e¡ected by the fetal liver
extracts is lower than that under similar conditions reported
using HeLa extracts [13]. The reasons for this are not entirely
clear but are likely to re£ect slight di¡erences in reaction
conditions, variations in the preparation of cell extracts or a
lower overall NER competence in fetal hepatocytes. Nuclear
extracts of fetal hepatocytes were used here, whereas whole
cell extracts were prepared for the study of HeLa NER. In
our hands, the nuclear preparation from hepatocytes carried
out NER more e⁄ciently than whole cell extracts (data not
shown). Diminished hepatocyte viability induced by termina-
tion of pregnancy is also likely to contribute to the lower
NER e⁄ciency that we have observed.
3.4. Location of the 5P incision sites and detection of excised
platinated oligonucleotides produced by dual incision
Coupled incision and mapping of the 5P incision site were
demonstrated by analysis of excised fragments containing the
Fig. 2. Detection of repair patch synthesis. A: Sequences surround-
ing the cisplatin adduct together with 5P and 3P incision sites gener-
ated by fetal hepatocyte extracts during NER. Solid circles above
the sequence indicate secondary incisions generated by HeLa whole
cell extracts. HindIII and EcoRI restriction sites used to detect the
repair synthesis step of NER are also shown. B: Autoradiograph of
HindIII/EcoRI restriction fragments from Con-GTG and Pt-GTG
DNA following repair reactions. The sizes in nucleotides (nt) of the
fragments from a DNA sequencing ladder are shown alongside.
Fig. 3. Detection of 5P and 3P NER incision sites. A: Mapping the
3P incision site. Primer extension on Con-GTG and Pt-GTG tem-
plate recovered from the repair reaction reveals the position of the
3P incision relative to the cisplatin adduct. B: Strategy for the detec-
tion of NER excision fragments. Excision fragments are hybridized
to a 34 nt synthetic oligonucleotide (anti-Pt-GTG) containing se-
quences complementary to the excised fragment. The 3P terminal
non-complementary nucleotides prevent labeling of anti-Pt-GTG. A
5P terminal poly-G provides template for labeling of the excised
fragment using [K-32P]dCTP and modi¢ed T7 DNA polymerase (Se-
quenase). C: Autoradiograph showing sequencing ladder as molecu-
lar weight marker, and platinated oligonucleotide excised from Pt-
GTG.
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1,3-intrastrand (GpTpG)-cisplatin adduct. After completing
incubation of the NER reaction, an oligonucleotide (anti-Pt-
GTG) was hybridized to complementary sequences of the ex-
cised cisplatin-containing oligonucleotide. The sequence of
anti-Pt-GTG included a 5P overhang that serves as template
for extension labeling of the 3P end of the excised Pt-contain-
ing fragment (Fig. 3B). A mismatch at the 3P end of anti-Pt-
GTG prevents priming at this end and the reaction conditions
thus allow only for the labeling of the cisplatin-containing
oligonucleotide. The single labeled fragment that was detected
using this methodology migrated with an equivalent molecular
weight of a 31 nucleotide fragment (Fig. 3C). The excised
fragment comprises 30 nucleotides since the platinum adduct
increases its molecular weight by the equivalent of one nucle-
otide [16]. In addition to the cisplatin adduct, and using in-
formation on the location of the 3P incision (Fig. 3A), the
detected fragment includes the four nucleotides that are com-
plementary to the 5P overhang of anti-Pt-GTG. Thus, the
unique NER excision product comprises 26 nucleotides to-
gether with the cisplatin adduct. The 5P incision of the Pt-
GTG substrate is calculated to occur at a single site that is
16 phosphodiester bonds from the cisplatin adduct. Secondary
incisions that occur 5P to the cisplatin adduct are undetect-
able. The locations of the 5P and 3P incisions that are gener-
ated by fetal hepatocyte preparations are depicted diagram-
matically in Fig. 2A and are similar to the main incision sites
that have been reported for HeLa cell extracts.
4. Discussion
Using platinated DNA similar to the substrate analyzed in
this study, Moggs et al. demonstrated that HeLa whole cell
extracts e¡ect major and minor incisions both 5P and 3P to the
cisplatin adduct during NER [13]. The main 5P incision is 16
phosphodiester bonds from the lesion and other 5P incisions
occur less frequently at the 18th and 19th phosphodiester
bonds from the cisplatin adduct. The major 3P incision was
at the ninth phosphodiester bond, and a minor 3P incision
occurred eight phosphodiester bonds from the lesion. The
factors that govern exact positioning of the 5P and 3P incisions
relative to the DNA lesion during NER are not completely
understood [1]. Di¡erent lesions, such as UV-induced pyrim-
idine dimers, cisplatin and cholesterol adducts, are released
within single-stranded oligonucleotides of similar size but
the incision positions vary depending on the lesion. The hel-
ical distortions and altered base stacking arrangements that
are caused by a particular lesion are thought to in£uence the
protein^DNA and consequently protein^protein interactions
to cause variable 3P and 5P incisions. Using cccDNA with a
de¢ned 1,3-intrastrand cisplatin adduct as template, primary
human hepatocyte extracts consistently generate 5P and 3P
incisions that correspond to the major incisions of HeLa ex-
tracts (Fig. 2A). It is not clear at this stage why the primary
extracts e¡ect a more precise endonucleolytic cleavage. How-
ever, our observations suggest that an accessory factor, not
present in cell culture-selected HeLa cells, regulates precise
incision.
The signi¢cance of tissue-speci¢c NER activity and the im-
portance of NER during mammalian development are not
well established. Analysis of NER activity in rat tissues dem-
onstrated incision and repair synthesis activities in several
organs, and rat liver repair synthesis was more active than
in other tissues [17]. NER is also active in neuronal tissue,
and defective NER in neurons may be responsible for the
progressive neurodegeneration that is characteristic of some
xeroderma pigmentosum patients [18]. NER has also been
studied in embryonal stem (ES) cells [19]. Surprisingly per-
haps, the repair of UV-induced lesions on transcribed and
non-transcribed genes was relatively ine⁄cient in these cells.
ES cells commit easily to apoptosis following moderate UV
light exposure and the role of NER in these cells may be
limited. ES cells have an absolute requirement for replicative
and transcriptional ¢delity and it is thought that apoptosis
with NER shutdown is the favored response to DNA damage.
Our demonstration of e⁄cient NER in hepatocyte extracts
from fetuses of 14 weeks gestation suggests that the impor-
tance of NER is promoted after embryonic development is
complete.
Hepatocytes play a central role in neutralizing the e¡ects of
a range of toxins. As a result of its anatomical location and
portal blood supply from the intestine, the liver is exposed to
potentially carcinogenic ingested mutagens. Also, common
hepatocarcinogens, such as HBV, cause persistent necroin-
£ammatory liver disease (cirrhosis) that is associated with in-
creased formation of potentially carcinogenic mutations
[8,20]. Moreover, in the case of HBV, the X protein (HBx)
is thought to compromise NER and is responsible for the
formation of oncogenic mutations in HBV-infected hepato-
cytes [9^12]. Successful reconstitution of NER using primary
liver extracts presents several possibilities for the study of
human hepatocyte DNA repair, as well as defects in the
NER pathway that underlie hepatocarcinogenesis. The prep-
arations described here have the advantage that they are not
subjected to prior selection in culture and are functionally
similar to hepatocytes in vivo. We have also shown that the
human liver extracts described here are competent for in vitro
transcription (data not shown). Using primary extracts of hu-
man fetal hepatocytes, our investigations are currently aimed
at de¢ning the role of HBx in NER as well as in the related
transcription-coupled DNA repair pathway.
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